A decades-old drug used to lower cholesterol levels in the blood has been shown to reduce the progression of vision-robbing retinopathy in people with diabetes.
The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the dru
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh